Avid Radiopharmaceuticals gained $26 million in Series C financing. The money will help Avid advance its pipeline of diagnostic molecular imaging compounds for neurological disorders, including Alzheimer's disease, Parkinson's disease and Dementia with Lewy Bodies. The financing was co-led by AllianceBernstein and Safeguard Scientifics. Last year, Avid inked a deal with Schering to develop new imaging agents for Alzheimer's.
- see the release on the financing